BioLife Solutions Inc. (BLFS)

20.40
0.56 2.70
NASDAQ : Health Technology
Prev Close 20.96
Open 21.00
Day Low/High 19.51 / 22.86
52 Wk Low/High 2.95 / 21.16
Volume 760.92K
Avg Volume 212.40K
Exchange NASDAQ
Shares Outstanding 15.11M
Market Cap 298.93M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioLife Solutions To Join Russell Microcap® Index

BioLife Solutions To Join Russell Microcap® Index

BOTHELL, Wash., June 11, 2018 /PRNewswire/ --  BioLife Solutions, Inc.

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $10.67, changing hands for $10.71/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BioLife Solutions Announces Partial Redemption Of Series A Preferred Stock

Redemption reduces annual cash dividend payment by $106,000

BioLife Solutions Makes Investment In SAVSU Technologies To Support Growth And Capture Additional Regenerative Medicine Cold Chain Opportunities

SAVSU Realizing Expanded evo® Product Adoption by Leading Specialty Logistics Providers and Cell Therapy Manufacturers

BioLife Solutions CryoStor® Cell Freeze Media Highlighted In Mayo Clinic/MD Anderson Journal Article On Preservation Of Patient-Derived Xenografts For Cancer Research

BioLife Solutions CryoStor® Cell Freeze Media Highlighted In Mayo Clinic/MD Anderson Journal Article On Preservation Of Patient-Derived Xenografts For Cancer Research

Published in Springer Nature Journal Laboratory Investigation; Superior Performance Over Traditional "Home Brew" Cryopreservation Formula

BioLife Solutions Executes OEM Agreement With MilliporeSigma

BioLife Solutions Executes OEM Agreement With MilliporeSigma

Private Labeled CryoStor® Cell Freeze Media and HypoThermosol® Cell and Tissue Storage and Shipping Media Distributed to Worldwide Biotech Research Market

Biolife Solutions Reaches Analyst Target Price

Biolife Solutions Reaches Analyst Target Price

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $5.75, changing hands for $5.81/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

BLFS Crosses Above Average Analyst Target

BLFS Crosses Above Average Analyst Target

In recent trading, shares of Biolife Solutions Inc have crossed above the average analyst 12-month target price of $5.08, changing hands for $5.29/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Shark Bites: Drone Maker AeroVironment Lines Up for 'Doofus' Trade

Shark Bites: Drone Maker AeroVironment Lines Up for 'Doofus' Trade

An attractive pattern has formed for AVAV.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks that are within range of triggering big breakouts.

BioLife Solutions (BLFS) Is Strong On High Volume Today

BioLife Solutions (BLFS) Is Strong On High Volume Today

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a strong on high relative volume candidate

BioLife Solutions (BLFS) Weak On High Volume

BioLife Solutions (BLFS) Weak On High Volume

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a weak on high relative volume candidate

Strong On High Volume: BioLife Solutions (BLFS)

Strong On High Volume: BioLife Solutions (BLFS)

Trade-Ideas LLC identified BioLife Solutions (BLFS) as a strong on high relative volume candidate

BioLife Sciences (BLFS) Stock Spikes as Clinical Trial Meets Primary Endpoint

BioLife Sciences (BLFS) Stock Spikes as Clinical Trial Meets Primary Endpoint

BioLife Sciences (BLFS) shares are up over 60% to after customer TiGenix's clinical trial meets primary endpoint.

5 Stocks Under $10 Set to Soar -- Must-See Charts

5 Stocks Under $10 Set to Soar -- Must-See Charts

Here's a technical look at how to trade five stocks under $10 that look to be setting up to break out.

Sell These 7 Health Care Supplies Companies Now

Sell These 7 Health Care Supplies Companies Now

An aging population means the outlook is positive for health care equipment and supplies companies, but not every stock in the industry is a buy.

BioLife Solutions (BLFS) Stock Spiking to Reach One Year High

BioLife Solutions (BLFS) Stock Spiking to Reach One Year High

BioLife Solutions (BLFS) stock is surging after the company announced several new customer disclosures.

BioLife Solutions (BLFS) Stock Spikes Today on Preliminary Financial Results

BioLife Solutions (BLFS) Stock Spikes Today on Preliminary Financial Results

BioLife Solutions (BLFS) shares are up double digits after the company released preliminary financial results today.

3 Stocks Pushing The Health Services Industry Lower

3 Stocks Pushing The Health Services Industry Lower

TheStreet highlights 3 stocks pushing the Health Services industry lower today.

3 Health Services Stocks Pushing Industry Growth

3 Health Services Stocks Pushing Industry Growth

TheStreet highlights 3 stocks that pushed the Health Services industry

3 Stocks Moving The Health Services Industry Upward

3 Stocks Moving The Health Services Industry Upward

TheStreet highlights 3 stocks that pushed the Health Services industry

Why BioLife Solutions (BLFS) Stock Is Surging Today

Why BioLife Solutions (BLFS) Stock Is Surging Today

BioLife Solutions (BLFS) surged Thursday after the hypothermic storage product manufacturer announced a three-year partnership with Somahlution.

3 Stocks Improving Performance Of The Health Services Industry

3 Stocks Improving Performance Of The Health Services Industry

TheStreet highlights 3 stocks that pushed the Health Services industry

TheStreet Quant Rating: D (Sell)